Savara Inc. (SVRA)’s Insider David Lowrance Sells 7,000 Shares of the Company; Conformis (CFMS) Sellers Decreased By 12.23% Their Shorts

7,000 shares of Savara Inc were unloaded by David Lowrance, the company’s Chief Financial Officer. The reported shares are valued at about $90,129 which has been calculated on the basis of the average transactions stock price ($12.9 per share). David Lowrance currently holds 23,755 shares which make up roughly 0.08% of the California-Company’s market cap (total dollar market value of all company’s outstanding shares).

Conformis Incorporated (NASDAQ:CFMS) had a decrease of 12.23% in short interest. CFMS’s SI was 2.94M shares in February as released by FINRA. Its down 12.23% from 3.35 million shares previously. With 294,400 avg volume, 10 days are for Conformis Incorporated (NASDAQ:CFMS)’s short sellers to cover CFMS’s short positions. The SI to Conformis Incorporated’s float is 7.55%. The stock increased 5.07% or $0.07 during the last trading session, reaching $1.45. About 377,315 shares traded. ConforMIS, Inc. (NASDAQ:CFMS) has declined 24.03% since February 20, 2017 and is downtrending. It has underperformed by 40.73% the S&P500.

The stock decreased 2.44% or $0.31 during the last trading session, reaching $12.39. About 206,666 shares traded or 17.32% up from the average. Savara Inc. (NASDAQ:SVRA) has declined 74.75% since February 20, 2017 and is downtrending. It has underperformed by 91.45% the S&P500.

Analysts await Savara Inc. (NASDAQ:SVRA) to report earnings on March, 5. They expect $-0.23 EPS, down 1,050.00% or $0.21 from last year’s $-0.02 per share. After $-0.28 actual EPS reported by Savara Inc. for the previous quarter, Wall Street now forecasts -17.86% EPS growth.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company has market cap of $377.90 million. The Company’s product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. It currently has negative earnings.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $85.35 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: